Belinostat

Generic Name
Belinostat
Brand Names
Beleodaq
Drug Type
Small Molecule
Chemical Formula
C15H14N2O4S
CAS Number
866323-14-0
Unique Ingredient Identifier
F4H96P17NZ
Background

Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for th...

Indication

Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia .

Associated Conditions
Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Associated Therapies
-

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2006-12-19
Last Posted Date
2015-07-08
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
35
Registration Number
NCT00413322
Locations
🇺🇸

Mayo Clinic Arizona, Scottsdale, Arizona, United States

🇺🇸

Portsmouth Regional Hospital Hematology/Oncology Clinic, Portsmouth, New Hampshire, United States

🇺🇸

University of Nebraska, Omaha, Nebraska, United States

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

First Posted Date
2006-08-17
Last Posted Date
2018-06-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
13
Registration Number
NCT00365053
Locations
🇺🇸

City of Hope, Duarte, California, United States

Belinostat in Treating Patients With Myelodysplastic Syndromes

First Posted Date
2006-07-27
Last Posted Date
2014-05-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
21
Registration Number
NCT00357162
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

First Posted Date
2006-06-08
Last Posted Date
2018-04-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
51
Registration Number
NCT00334789
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 2 locations

Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

First Posted Date
2006-05-04
Last Posted Date
2017-11-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
54
Registration Number
NCT00321594
Locations
🇸🇬

Cancer Therapeutics Research Group, Singapore, Singapore

🇺🇸

University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

First Posted Date
2006-03-17
Last Posted Date
2014-05-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
22
Registration Number
NCT00303953
Locations
🇺🇸

Heartland Regional Medical Center, Saint Joseph, Missouri, United States

🇺🇸

Kalispell Medical Oncology, Kalispell, Montana, United States

🇺🇸

Kalispell Regional Medical Center, Kalispell, Montana, United States

and more 120 locations
© Copyright 2024. All Rights Reserved by MedPath